A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients : results at 1 year / Wolfgang Arns, Claudia Sommerer, Petra Glander, Toofan Ariatabar, Martina Porstner, Christoph May, Eva-Maria Paulus, Maria Shipkova, Wolfgang Fischer, Lutz Liefeldt, Ruth Hackenberg, Peter Schemmer, Sophie Domhan, Martin Zeier, Klemens Budde
In a 6-month prospective, openlabel, multicenter study, 128 de novo kidney transplant patients receiving cyclosporine (CsA) and steroids were randomized to an intensified regimen of enteric-coated mycophenolate sodium (EC-MPS) or to a standard EC-MPS regimen to Week 6 posttransplant, after which the regimen was identical. In a follow-up study to Month 12 post-transplant (49 intensified regimen, 52 standard regimen), the reduced rate of BPAR observed at Month 6 (intensified regimen 3.2%, standard regimen 16.9%, p = 0.016) was maintained at Month 12 (4.8% vs. 18.5%, p = 0.026). Estimated GFR (Cockcroft-Gault) at Month 12 was comparable in the intensified group (mean (SD) 54.8 (22.9) ml/min) vs. the standard group (mean (SD) 57.5 (23.6) ml/min, p = 0.83). The incidence of adverse events and serious adverse events at Month 12 was similar in both treatment groups, although adverse events with a suspected relation to study drug were reported in 69.8% and 50.8% of patients in the intensified and standard regimen groups, respectively (p = 0.032). Infections and hematological parameters were similar between groups. In conclusion, an early regimen of intensified EC-MPS with CsA and steroids achieves a low rate of BPAR over the first year after kidney transplantation with similar renal function to a standard regimen, and without a clinically relevant impact on safety..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
---|---|
Enthalten in: |
Clinical nephrology - 79(2013), 6, Seite 421-431 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Arns, Wolfgang [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
Gesehen am 26.10.2020 |
---|
Umfang: |
11 |
---|
doi: |
10.5414/CN107908 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1736601237 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1736601237 | ||
003 | DE-627 | ||
005 | 20220819001348.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201026s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5414/CN107908 |2 doi | |
035 | |a (DE-627)1736601237 | ||
035 | |a (DE-599)KXP1736601237 | ||
035 | |a (OCoLC)1341373314 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Arns, Wolfgang |e verfasserin |0 (DE-588)140837248 |0 (DE-627)621681504 |0 (DE-576)320992535 |4 aut | |
245 | 1 | 2 | |a A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients |b results at 1 year |c Wolfgang Arns, Claudia Sommerer, Petra Glander, Toofan Ariatabar, Martina Porstner, Christoph May, Eva-Maria Paulus, Maria Shipkova, Wolfgang Fischer, Lutz Liefeldt, Ruth Hackenberg, Peter Schemmer, Sophie Domhan, Martin Zeier, Klemens Budde |
264 | 1 | |c 2013 | |
300 | |a 11 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Gesehen am 26.10.2020 | ||
520 | |a In a 6-month prospective, openlabel, multicenter study, 128 de novo kidney transplant patients receiving cyclosporine (CsA) and steroids were randomized to an intensified regimen of enteric-coated mycophenolate sodium (EC-MPS) or to a standard EC-MPS regimen to Week 6 posttransplant, after which the regimen was identical. In a follow-up study to Month 12 post-transplant (49 intensified regimen, 52 standard regimen), the reduced rate of BPAR observed at Month 6 (intensified regimen 3.2%, standard regimen 16.9%, p = 0.016) was maintained at Month 12 (4.8% vs. 18.5%, p = 0.026). Estimated GFR (Cockcroft-Gault) at Month 12 was comparable in the intensified group (mean (SD) 54.8 (22.9) ml/min) vs. the standard group (mean (SD) 57.5 (23.6) ml/min, p = 0.83). The incidence of adverse events and serious adverse events at Month 12 was similar in both treatment groups, although adverse events with a suspected relation to study drug were reported in 69.8% and 50.8% of patients in the intensified and standard regimen groups, respectively (p = 0.032). Infections and hematological parameters were similar between groups. In conclusion, an early regimen of intensified EC-MPS with CsA and steroids achieves a low rate of BPAR over the first year after kidney transplantation with similar renal function to a standard regimen, and without a clinically relevant impact on safety. | ||
650 | 4 | |a Adult | |
650 | 4 | |a Aged | |
650 | 4 | |a Cyclosporine | |
650 | 4 | |a Female | |
650 | 4 | |a Follow-Up Studies | |
650 | 4 | |a Germany | |
650 | 4 | |a Glomerular Filtration Rate | |
650 | 4 | |a Glucocorticoids | |
650 | 4 | |a Graft Rejection | |
650 | 4 | |a Graft Survival | |
650 | 4 | |a Humans | |
650 | 4 | |a Immunosuppressive Agents | |
650 | 4 | |a Kidney Transplantation | |
650 | 4 | |a Male | |
650 | 4 | |a Middle Aged | |
650 | 4 | |a Mycophenolic Acid | |
650 | 4 | |a Prospective Studies | |
650 | 4 | |a Tablets, Enteric-Coated | |
650 | 4 | |a Treatment Outcome | |
700 | 1 | |a Sommerer, Claudia |d 1971- |e verfasserin |0 (DE-588)121857654 |0 (DE-627)705680002 |0 (DE-576)292921829 |4 aut | |
700 | 1 | |a Glander, Petra |e verfasserin |4 aut | |
700 | 1 | |a Ariatabar, Toofan |e verfasserin |4 aut | |
700 | 1 | |a Porstner, Martina |e verfasserin |4 aut | |
700 | 1 | |a May, Christoph |e verfasserin |4 aut | |
700 | 1 | |a Paulus, Eva-Maria |e verfasserin |4 aut | |
700 | 1 | |a Shipkova, Maria |e verfasserin |4 aut | |
700 | 1 | |a Fischer, Wolfgang |e verfasserin |4 aut | |
700 | 1 | |a Liefeldt, Lutz |e verfasserin |4 aut | |
700 | 1 | |a Hackenberg, Ruth |e verfasserin |4 aut | |
700 | 1 | |a Schemmer, Peter |d 1967- |e verfasserin |0 (DE-588)1022604244 |0 (DE-627)717006794 |0 (DE-576)365668230 |4 aut | |
700 | 1 | |a Domhan, Sophie |d 1976- |e verfasserin |0 (DE-588)128571136 |0 (DE-627)376205288 |0 (DE-576)297220012 |4 aut | |
700 | 1 | |a Zeier, Martin |e verfasserin |0 (DE-588)1026480302 |0 (DE-627)726772356 |0 (DE-576)371826438 |4 aut | |
700 | 1 | |a Budde, Klemens |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical nephrology |d Deisenhofen, Munich : Dustri-Verl. Feistle, 2002 |g 79(2013), 6, Seite 421-431 |h Online-Ressource |w (DE-627)320498875 |w (DE-600)2011960-4 |w (DE-576)356321711 |7 nnns |
773 | 1 | 8 | |g volume:79 |g year:2013 |g number:6 |g pages:421-431 |g extent:11 |
856 | 4 | 0 | |u https://doi.org/10.5414/CN107908 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4306 | ||
936 | u | w | |d 79 |j 2013 |e 6 |h 421-431 |g 11 |
951 | |a AR | ||
952 | |d 79 |j 2013 |e 6 |h 421-431 |g 11 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3786441588 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 26-10-20 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2013 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_15 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_11 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1441826939 |a Sommerer, Claudia | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_2 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1435687272 |a Schemmer, Peter | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_12 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1513106554 |a Domhan, Sophie | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416741399 |a Radiologische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_13 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1441826955 |a Zeier, Martin | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416740783 |a Medizinische Universitätsklinik und Poliklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_14 |